Should Graf IIc Hips be Treated for 12 Weeks
Launched by UNIVERSITY OF COLORADO, DENVER · Sep 5, 2017
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how long children with a specific type of hip condition called Developmental Dysplasia of the Hip (DDH) should wear a special device known as the Pavlik Harness. The researchers want to find out if wearing the harness for a full 12 weeks is better than wearing it for just 6 weeks or until the hip looks normal. The trial will involve children diagnosed with stable Graf type IIc hips, which means their hip joints are not unstable but show some malformation.
To participate in the study, children need to be diagnosed with DDH and have a specific type of hip measurement (called the alpha angle between 43-49 degrees) along with a normal hip examination and an abnormal ultrasound. However, children with other health conditions affecting their nervous system or those who have unstable hips will not be eligible. Participants in the trial can expect to be closely monitored over a two-year period, with follow-up X-rays to see which treatment approach works best for their hip development. This trial is currently recruiting participants of all ages, from newborns to older children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- 1. Patients with:
- • DDH
- • Graf IIc hips (alpha angle = 43-49 degrees)
- • normal hip exam (stable hips)
- • abnormal ultrasound
- Exclusion Criteria:
- • 1. Patients with additional conditions: Neurologic or teratologic.
- • 2. Follow up that occurs at any other institution.
- • 3. Unstable hips
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Trial Officials
Gaia Georgopoulos, MD
Principal Investigator
Children's Hospital Colorado
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials